Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$4.85 USD
-0.05 (-1.02%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $4.78 -0.07 (-1.44%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELTX 4.85 -0.05(-1.02%)
Will ELTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ELTX
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Elicio Therapeutics Announces Proposed Public Offering
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P